- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00188617
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery
ELIGIBILITY
- Non-small cell lung cancer Clinical Stage 1A (T1N0M0 a tumor that is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)* or 1B (T2N0M0 a tumor with any of the following features of size or extent: More than 3 cm in greatest dimension. Involves the main bronchus, 2 cm or more distal to the carina. Invades the visceral pleura. Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung).
- Must be deemed appropriate surgical candidate
- ECOG performance status £ 2
- Age ³ 18 years
- No prior chemotherapy, radiotherapy or EGFR inhibitors
PRE-TREATMENT INVESTIGATIONS
- History, physical examination, hematology, biochemistry, toxicity/baseline symptoms: within 7 days of registration
- Radiology: CT chest within 7 days of registration
- Tumor biopsy prior to treatment
TREATMENT
- Gefitinib 250 mg will be administered orally daily x 28 days
EVALUATIONS ON TREATMENT
- Physical examination (vital signs, weight, ECOG performance status) weekly x 4
- Hematology (CBC, differential): Day 1,15, 29
- Biochemistry (creatinine, electrolytes, bilirubin, alkaline phosphatase, AST/ALT, protein): Day 1,15, 29
- Radiology: CT at baseline and after day 28
- Toxicity evaluation: continuous
DURATION OF TREATMENT
- Treatment is to be discontinued in cases of serious or unacceptable toxicity, or by patient or physician request
- Otherwise duration of therapy will be a maximum of 28 days
Studie Overzicht
Gedetailleerde beschrijving
Primary and Secondary Outcomes:
Objectives:
- To assess the pathologic and radiological response rate after neoadjuvant Gefitinib treatment
- To assess the toxicity of neoadjuvant Gefitinib treatment in clinical stage 1A & 1B NSCLC
- Enrollment
Treatment will be administered on an outpatient basis. Patients may be identified by thoracic surgeons, respirologists and/or interventional chest radiologists for study participation upon clinical and radiographic assessment.
**Diagnostic biopsy, Pretreatment Investigations
If patients have already had a core or FNA biopsy before referral, this material will be sought from the original pathologist for review and inclusion in the study with appropriate consent sought. If a patient does not have a biopsy upon presentation to the thoracic surgeon, and consents to inclusion in the trial, baseline non-invasive assessment will be carried out before a percutaneous biopsy will be mandated as part of entry into the study. After non-invasive staging, patients will be subject to biopsy. In collaboration with pathology, an immediate diagnosis will be made at the time of fine needle aspiration biopsy (or bronchoscopy). After a pathologic diagnosis of cancer is confirmed, subjects will be invited to have additional biopsies will be performed to obtain material for correlative studies, assuming no complications or technical difficulties have arisen. These studies will be done in collaboration with thoracic interventional radiologists from Diagnostic Imaging, who supervises the lung fine needle aspirates and biopsies.
All patients will undergo pre-study assessments for symptoms, performance status, radiographic assessment and blood tests (complete blood count, electrolytes, liver and renal function tests). Assessment of response will occur after the 4-week treatment period. Toxicity will be assessed continuously, with patient assessment weekly on treatment, repeat blood tests at 2 weeks and imaging of measurable disease at 4 weeks. All subjects will be invited to have their initial diagnostic biopsy and subsequent surgical tumor specimen examined as part of the laboratory correlate component of the study. Patients will be considered evaluable for pharmacodynamic assessment if they complete at least 21 of the planned 28 days of therapy.
Once competed, oral Gefitinib will be administered at a dose of 250 mg (1 pill) daily for 28 days prior to the planned mediastinoscopy. Patients may take the pill either with or without food, and are encouraged to take the medication at approximately the same time each day. If the patient forgets to take a dose, they should take the last missed dose as soon as they remember, as long as it is at least 12 hours before the next dose is due. If patient vomits after taking the dose, the dose may be retaken if the tablet is seen in the emesis. The last dose of Gefitinib will be administered not less than 48 hours prior to mediastinoscopy or surgery.
If the mediastinoscopy reveals the presence of Stage III disease, the patient's mediastinoscopy samples may still be analysed as part of the correlative study. Patients will be followed for 90 days or as long as required after the last dose of Gefitinib to ensure resolution of any Gefitinib-related toxicities. However these patients will be offered standard therapy for stage III disease off of study protocol, for example a combination of chemotherapy, radiation plus or minus surgical resection. If these patients do proceed to thoracotomy post-chemotherapy and/or radiotherapy, their resection specimen will not be eligible for this correlative protocol.
**Duration of Therapy and Follow-up
As outlined above, patients will be treated for 28 days before surgery and will also be followed for 90 days post-operatively after thoracotomy to ensure the recovery from surgery. Accrual is estimated at 2 patients per month, for 18 to 24 months, based on accrual rates to other thoracic surgical studies at UHN. Study duration is planned from August 2004 to June 2006.
All patients will be followed in the current standard of care at University Health Network. That is, clinic visits with chest x-ray every 3 months for 2 years, every 6 months in the third year, and annually thereafter. Recorded information will only include vital status and presence or absence of disease recurrence.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have biopsy-proven non-small cell lung carcinoma (NSCLC) or a lung nodule seen on CT imaging and a high-clinical suspicion of NSCLC
- Clinical Stage 1A (T1N0M0 a tumor that is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)
or 1B (T2N0M0 a tumor with any of the following features of size or extent: More than 3 cm in greatest dimension. Involves the main bronchus, 2 cm or more distal to the carina. Invades the visceral pleura. Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung).
- Must be deemed appropriate surgical candidate
- ECOG performance status £ 2
- Age ³ 18 years
- No prior chemotherapy, radiotherapy or EGFR inhibitors
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients who have received prior anticancer treatment with chemotherapy, radiotherapy or EGFR inhibitor therapy;
- Patients who have had a previous diagnosis of cancer, are excluded except if have been adequately treated for non-melanoma skin cancer or carcinoma in situ of the cervix are eligible irrespective of when that treatment was given.
- Patients may not be receiving any other investigational or anticancer agents while on study;
- History of allergic reactions to Gefitinib or erlotinib
- Pre-existing diarrhea ³ NCI CTC Grade 2
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure or evidence of cardiac dysfunction, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease, poorly controlled diabetes mellitus, clinically significant or untreated ophthalmologic (e.g. Sjogrens etc.) or gastrointestinal conditions (e.g. Crohns disease, ulcerative colitis) or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women because of the unknown effects of Gefitinib on the human fetus.
- HIV-positive patients on active treatment
- Active malignancy at any other site including combined small cell and non-small cell carcinomas or a pulmonary carcinoid tumor.
- Taking drugs that induce CYP3A4 enzymes, patients with ongoing use of phenytoin, rifampicin, carbamazepine, barbiturates, rifampicin, or St John's Wort are excluded.
- Incomplete healing from previous surgery.
- Use of any agent that decreases gastric pH, including proton pump inhibitors, Histamine-2 receptor blockers or sodium bicarbonate. Use of calcium or magnesium based elixirs are not included.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
· To assess the pathologic and radiological response rate after neoadjuvant Gefitinib treatment
Tijdsspanne: before starting drug and after 28 days of treatment
|
before starting drug and after 28 days of treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
· To assess the toxicity of neoadjuvant Gefitinib treatment in clinical stage 1A & 1B NSCLC
Tijdsspanne: at baseline, 2weeks into treatment at 4weeks and 30 days after stopping drug
|
at baseline, 2weeks into treatment at 4weeks and 30 days after stopping drug
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Thomas Waddell, MD FRCSC, University Health Network, Toronto
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- UHN REB04-0420-C
- ASTRA ZENECA study D7913L00038
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op LUNG CANCER
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op GEFITINIB
-
Sun Yat-sen UniversityOnbekend
-
Qilu Pharmaceutical Co., Ltd.OnbekendNiet-kleincellige longkankerChina
-
Jiangsu Famous Medical Technology Co., Ltd.OnbekendNiet-kleincellige longkanker
-
Anhui Medical UniversityOnbekendZelfeffectiviteit | Toxiciteit van medicijnenChina
-
Kunming Medical UniversityBeëindigdNiet-kleincellige longkankerChina
-
AstraZenecaVoltooidNeoplasmata, plaveiselcelVerenigde Staten, Tsjechische Republiek, Polen, Duitsland, België, Taiwan, Indië, Servië
-
NCIC Clinical Trials GroupVoltooid
-
University of Maryland, BaltimoreNational Cancer Institute (NCI); University of Maryland Greenebaum Cancer CenterVoltooidNierkankerVerenigde Staten
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)VoltooidEierstokkanker | Primaire peritoneale holtekankerVerenigde Staten, Canada, Verenigd Koninkrijk, Australië
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)VoltooidSlokdarmkankerVerenigde Staten